Fig. 2From: Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibitionMilestone chart on the progress of selected HDAC inhibitors research. There is currently no clinical trial specifically targeting the treatment of hepatocellular carcinoma (HCC) with HDAC inhibitor. However, VA monotherapy has been found to inhibit the development of HCC cells by preclinical studyBack to article page